Prosia Therapeutics, Inc. of Malvern, PA is pioneering innovations in the field of fibrosing diseases such as pulmonary fibrosis as well as novel treatments for COVID-19 associated lung damage. Through an exclusive option agreement entered in 2021, Prosia has obtained rights to international patents on potential therapeutics developed at Texas A&M. Prosia plans to swiftly take these discoveries from lab to market to help the growing number of millions of patients suffering from fibrotic diseases, and Covid-19 associated lung damage.
